Ultragenyx Pharmaceutical Stock Fair Value – Nineteen Research Analysts Recommend “Moderate Buy” for Ultragenyx Pharmaceutical Shares

☀️Trending News

Ultragenyx Pharmaceutical ($NASDAQ:RARE) Inc. is a biopharmaceutical company based in the United States, focused on developing treatments for rare and ultra-rare genetic diseases. The company’s portfolio includes treatments for genetic diseases such as its product, Mepsevii, which is used to treat children with mucopolysaccharidosis type VII. Nineteen research firms have recently given a consensus recommendation of “Moderate Buy” to Ultragenyx Pharmaceutical Inc.’s shares. Analysts view this recommendation as a positive sign, as the company has a history of developing innovative treatments for rare diseases and an active research and development program. Ultragenyx’s products have been seen as showing promise in clinical trials and it has recently expanded its product pipeline with more potential treatments.

Furthermore, the company has had a successful track record of gaining approval from regulators such as the FDA. Overall, the nineteen research firms have given Ultragenyx Pharmaceutical Inc. a “Moderate Buy” recommendation, citing its potential in developing treatments for rare diseases and its ongoing research and development initiatives. The analysts see this as a positive sign for the company’s future and believe that its shares could deliver investors with a good return in the long run.

Price History

On Thursday, Ultragenyx Pharmaceutical Inc.’s (ULTRAGENYX PHARMACEUTICAL) stock opened at $49.8 and closed at $48.9, down by 2.5% from its previous closing price of 50.1. This indicates that while the market sentiment is not entirely bullish, the analysts are still optimistic about the long-term potential of the stock. As investors consider the current stock price, they can also take into account these positive analyst ratings. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Ultragenyx Pharmaceutical. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Ultragenyx Pharmaceutical. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Ultragenyx Pharmaceutical. More…

Key Ratios Snapshot

Some of the financial key ratios for Ultragenyx Pharmaceutical are shown below. More…

Analysis – Ultragenyx Pharmaceutical Stock Fair Value

At GoodWhale, we have been closely examining ULTRAGENYX PHARMACEUTICAL‘s fundamentals and conducting analysis on the company. After an in-depth evaluation of ULTRAGENYX PHARMACEUTICAL’s financials, we have determined that the fair value of its share is around $86.5 using our proprietary Valuation Line. Currently, ULTRAGENYX PHARMACEUTICAL stock is traded at $48.9, which is 43.5% lower than its fair value. This implies that it may be a good opportunity to invest in ULTRAGENYX PHARMACEUTICAL as it is undervalued at the moment. We recommend investors to consider this and make their decisions accordingly. More…

Peers

The competition in the pharmaceutical industry is fierce, with companies constantly vying for market share. This is especially true in the area of rare disease treatments, where there are often only a few companies competing for patients. Ultragenyx Pharmaceutical Inc is one such company, and it competes against Cassiopea SpA, Poxel SA, and Ampio Pharmaceuticals Inc, among others.

– Cassiopea SpA ($LTS:0RA2)

Poxel SA is a pharmaceutical company that focuses on the development of treatments for diabetes and obesity. The company has a market capitalization of $42.92 million and a return on equity of -705.2%. Poxel SA’s products include Imeglimin, which is in clinical development for the treatment of type 2 diabetes, and PXL065, which is in preclinical development for the treatment of obesity.

Summary

The investing analysis of Ultragenyx Pharmaceutical Inc. is positive among analysts. Nineteen different research firms have given the stock a consensus recommendation of “Moderate Buy”. Investors looking to include Ultragenyx in their portfolio should consider the company’s performance and potential upside.

The company has seen recent growth in both revenue and earnings, signaling strong financial performance and potential for further gains. With analyst consensus on the stock being largely positive, investors should consider further research into Ultragenyx before making an investment decision.